Endocrine Abstracts

Microprolactinomas are the commonest pituitary tumour and respond well to dopamine agonist (DA) therapy with resolution of symptoms and tumour shrinkage occurring in the vast majority of cases. Reports also suggest that up to 20% of cases may achieve long-term normoprolactinaemic remission following withdrawal of chronic dopamine agonist therapy yet interruption of therapy is not universally practised nor is there consensus on the duration of therapy. In this retrospective stu...